Bronchopulmonary Dysplasia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bronchopulmonary Dysplasia – Drugs In Development, 2024 report and make more profitable business decisions.
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting), and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection; premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics, and antibiotics.
The Bronchopulmonary Dysplasia drugs in development market research report provide comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bronchopulmonary Dysplasia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bronchopulmonary Dysplasia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bronchopulmonary Dysplasia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bronchopulmonary Dysplasia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advent Therapeutics IncAirway Therapeutics Inc
Alveolus Bio Inc
Aspire Pharma Ltd
Ayuvis Research Inc
Chiesi Farmaceutici SpA
Children's Hospital Pennsylvania
CMTx Biotech Inc
Exo Biologics SA
MediPost Co Ltd
Meridigen Biotech Co Ltd
Oak Hill Bio Inc
Provepharm life Solutions SA
ReNeuroGen LLC
Vale Pharmaceuticals Ltd
Velvio GmbH
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bronchopulmonary Dysplasia reports